The IMF’s Understanding series of cancer information booklets is designed to acquaint you with specific multiple myeloma-related tests, treatments and therapies, supportive care measures, and common adverse events.
April 23, 2025
Understanding a complex disease like myeloma can feel like you must learn a new language very quickly. The IMF’s signature publication, …
August 01, 2023
Full of our informative publications, including our Patient Handbook and selections from the popular Understanding Series, the Info Pack will…
July 01, 2024
Immunotherapy with Abecma® (idecabtagene vicleucel or “ide-cel” for short) is FDA-approved for the treatment of relapsed refractory multiple myeloma…
March 17, 2025
Carvykti® (ciltacabtagene autoleucel, or “cilta-cel” for short) is a customized immunotherapy approved by the FDA for the treatment of patients…
September 02, 2024
This booklet serves as an introduction to cereblon E3 ligase modulatory drugs (CELMoDs), a new class of medications currently being studied in…
November 20, 2024
This publication discusses what myeloma patients should consider if enrolling in a clinical trial.
January 28, 2025
This publication discusses the use of DARZALEX (daratumumab) injection and DARZALEX FASPRO —for the treatment of myeloma.
October 14, 2024
This booklet discusses dexamethasone, a synthetic steroid that is one of the most frequently used medications in the treatment of myeloma.
March 13, 2025
Elrexfio™ (elranatamab-bcmm) is a B-cell maturation antigen (BCMA)-directed CD3 T-cell engager.
January 24, 2025
This publication discusses the use of Empliciti (elotuzumab)—a monoclonal antibody—for the treatment of myeloma.
December 05, 2024
Patients with myeloma may experience fatigue caused by the disease itself or by treatment for myeloma, as well as by other medical problems or their…
July 01, 2024
This publication discusses the use of Kyprolis (carfilzomib)— a proteasome inhibitor—for the treatment of myeloma.
February 21, 2025
This publication covers monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
September 02, 2024
The International Myeloma Foundation provides this glossary that defines commonly used multiple myeloma-related terms
March 05, 2025
This publication discusses peripheral neuropathy, which can be a complication of multiple myeloma or its treatments.
March 01, 2024
This publication discusses the use of Ninlaro (ixazomib)—a proteasome inhibitor—for the treatment of myeloma.
March 08, 2024
This publication discusses the use of Pomalyst (pomalidomide)—an immunomodulatory drug (IMiD)—for the treatment of myeloma.
November 28, 2024
This publication discusses the use of Revlimid (lenalidomide)—an immunomodulatory drug (IMiD)—for the treatment of myeloma.
January 23, 2025
The Understanding SARCLISA® (isatuximab-irfc) booklet discusses a novel anti-CD38 monoclonal antibody that is approved for patients with relapsed and…
November 19, 2024
This publication is for myeloma patients in the U.S. who are considering undergoing an autologous stem cell transplant (ASCT).
November 15, 2023
Talvey is indicated for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least 4 prior lines of therapy.
February 26, 2024
Tecvayli™ (teclistamab-cqyv) is the first in a drug class of bispecific antibodies approved by the FDA to treat myeloma.
May 16, 2024
This publication discusses the use of Thalomid (Thalidomide)—an immunomodulatory drug (IMiD)—for the treatment of myeloma.
September 02, 2024
This publication discusses the effects of multiple myeloma on the immune system.
January 28, 2025
This booklet discusses Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone as treatment for newly diagnosed myeloma.
February 11, 2025
This publication focuses on therapies (such as bisphosphonates) given to patient with myeloma bone lesions, lytic lesions, or myeloma bone disease.
May 18, 2019
This publication discusses how myeloma patients can manage vertebral compression fractures.
March 05, 2025
This publication discusses the use of Velcade (bortezomib)—a proteasome inhibitor—for the treatment of myeloma.
May 17, 2021
This booklet discusses Xpovio (selinexor) for the treatment of multiple myeloma.
March 06, 2025
This booklet outlines the various tests that are used to diagnose and monitor myeloma, and to detect response and relapse.
with support from:
Johnson & Johnson, Sanofi, and Pfizer.